NovaBay Pharmaceuticals, Inc. — SEC Form D Filing

NovaBay Pharmaceuticals, Inc. filed an SEC Form D on January 27, 2026, reporting $134.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
January 27, 2026
Amount reported
$134.00M
Industry
Pharmaceuticals
Headquarters
EMERYVILLE, California, United States
Website
https://novabay.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

People suffer from various unmet medical needs, particularly related to eye and skin health.

Solution

NovaBay Pharmaceuticals develops and sells topical ophthalmic and an-ti-infective products for various health conditions.

Verdict

This cleared because there was an existing market with clear unmet needs in eye and skin health that the science could address, not because of proprietary distribution or a novel business model. Investors were implicitly betting on clinical efficacy and regulatory approval converting into market share within established medical verticals. The upside was limited by the high capital requirements of pharmaceutical development and the established competitive landscape for topical treatments.

Source: SEC EDGAR Form D filing